RBC Capital Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)

In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $70.00. The company’s shares closed yesterday at $20.92.

Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Alpine Immune Sciences, and ADC Therapeutics. According to TipRanks, Renza has an average return of 18.4% and a 47.06% success rate on recommended stocks.

Currently, the analyst consensus on Jasper Therapeutics is a Strong Buy with an average price target of $67.00, implying a 220.27% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $65.00 price target.

Based on Jasper Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.54 million. In comparison, last year the company had a GAAP net loss of $11.86 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jasper Therapeutics (JSPR) Company Description:

Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.